SEK 75m · Other round · Cleantech, Deeptech · Solna, Sweden
Solna-based biomanufacturing company EnginZyme has raised SEK 75m in a new equity round. Lotus One Investment and Valquest Partners Europe joined as new shareholders and board members, while Sofinnova Partners, Industrifonden, Navigare Ventures and Almi Invest GreenTech also participated. The financing supports EnginZyme's shift from research and development towards a commercially driven strategy, according to Sofinnova Partners.
EnginZyme immobilises enzymes on solid supports to run manufacturing processes without living organisms. The company says the approach can lower production costs and environmental impact for ingredients used in personal care, food and pharmaceuticals.
Commercialisation means proving process economics
EnginZyme's technical proposition is not only that enzymes can replace conventional chemistry, but that they can do so at industrial cost and quality. Its cell-free setup is designed to avoid some constraints of living-organism production while keeping enzymes reusable, which could improve process control for manufacturers.
The next test sits with customer deployment rather than laboratory performance. EnginZyme must translate techno-economic studies and process development into repeatable industrial manufacture across several end markets. New board investors add commercial experience, but each application still needs compelling yield, quality and cost data before customers change established production lines.
Sources checked: Sofinnova Partners announcement; EnginZyme website; Tech.eu Funding Explorer.
